This phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to other treatments (salvage therapy) before autologous stem cell transplant in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Epcoritamab is a so-called bispecific antibody, a molecule that can bind simultaneously to two different receptors (proteins present on the cell surface). Epcoritamab binds to a receptor called CD3 with one part of the antibody and to a receptor called CD20 with another part of the antibody. CD3 is expressed on T cells, which are important cells of the immune system that help the body fight cancers and infections. CD20 is expressed on the surface of DLBCL cells. By simultaneous binding to CD3 and CD20, epcoritamab brings T cells and DLBCL cells close together and activates the T cells to kill the lymphoma cells. Rituximab is a so-called monoclonal antibody, a molecule that binds to a single receptor. Like epcoritamab, rituximab binds to CD20. After binding to CD20, rituximab activates the immune system to kill the lymphoma cell through several different mechanisms. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Giving epcoritamab-R-GemOx as therapy before an autologous stem cell transplant may help kill cancer cells in the body and help make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.

开始日期2026-12-30

申办/合作机构

City of Hope National Medical Center

[+1]

NCT07094893

/ Not yet recruiting临床4期IIT

A Biomarker Enrichment Trial of Anti-EGFR Agents in Patients With Advanced Colorectal Cancer (aCRC) With Wild-type RAS and Right Primary Tumour Location (Right-PTL).

The aim of this trial is to assess the feasibility of EREG/AREG assessment as a clinical diagnostic standard, used to guide clinical decision making in right-PTL, RAS-wt aCRC. Further to this, the aim is to determine whether EREG/AREG status identifies right-PTL participants who will benefit from the addition of anti-EGFR therapy to first-line chemotherapy.

开始日期2026-04-15

申办/合作机构

Gruppo Oncologico del Nord-Ovest

[+1]

NCT07325214

/ Not yet recruitingN/A

A Randomized Pivotal Clinical Trial Evaluating Chemotherapy Regimen Consisting of Irinotecan Hydrochloride, Oxaliplatin, Fluorouracil (5-FU) and Leucovorin With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable Pancreatic Cancer or Locally Advanced Pancreatic Cancer

The purpose of this Interventional clinical trial is to evaluate safety and efficacy of 'IMD10 (focused ultrasound)' in the treatment of borderline resectable pancreatic cancer or locally advanced pancreatic cancer.

开始日期2026-04-01

申办/合作机构

IMGT CO LTD

100 项与奥沙利铂相关的临床结果

登录后查看更多信息

100 项与奥沙利铂相关的转化医学

登录后查看更多信息

100 项与奥沙利铂相关的专利（医药）

登录后查看更多信息

16,953

项与奥沙利铂相关的文献（医药）

2026-12-01·MOLECULAR BIOLOGY REPORTS

Non-Coding RNAs and cernas: emerging modulators of drug response in colorectal cancer

Review

作者: Abkenar, Elahe Daskar ; Sadeghi, Amir ; Mojarad, Ehsan Nazemalhosseini ; Nobili, Stefania ; Shams, Elahe ; Moghani, Mona Malekzadeh ; Sina, Negin ; Ebrahimi, Sara ; Fatemi, Nayeralsadat

Colorectal cancer (CRC) is still one of the most common cancers and a leading cause of cancer morbidity worldwide. A significant issue that should be paid much attention to is its resistance to anticancer agents. Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have been identified as important regulators of drug response and drug resistance in CRC. In this review, we provide a comprehensive assessment of the studies conducted in the field of investigating the role of ncRNAs in drug resistance to prominent anticancer agents used in CRC, including 5-fluorouracil (5-FU), oxaliplatin, cetuximab, bevacizumab, and regorafenib. We focussed specifically on the miRNAs, lncRNAs, and circRNAs associated with resistance to each drug individually, even within the context of combination therapies, such as FOLFOX. We also reviewed competing endogenous RNA (ceRNAs) networks and their relationship with drug sensitivity and resistance and new therapeutic strategies to manage drug resistance in CRC and also analyzed the role of ceRNA networks in modulating drug response and its implications for new approaches to overcome drug resistance in CRC. This article also discusses findings from human clinical trials, highlighting evidence from patient studies that validate the role of targeting ceRNA and ncRNA networks in improving drug sensitivity, overcoming resistance, and enhancing therapeutic outcomes in CRC. It supports the targeting of ncRNA and ceRNA networks as potential therapies to improve treatment outcomes and drug resistance in CRC.

2026-05-01·Bioactive Materials

LRP-1/CD44-targeted regorafenib nano-delivery system leveraging anti-angiogenesis and synergistic cytotoxicity against peritoneal metastasis of colorectal cancer

Article

作者: Zhu, Mei ; Qian, Yutong ; Wei, Yujia ; Chen, Wen ; Li, Yicong ; Hu, Danrong ; Li, Xicheng ; Qian, Zhiyong ; Wang, Meng ; Li, Ran ; Pan, Meng

Peritoneal metastasis of colorectal cancer (PM-CRC) represents a major therapeutic challenge in advanced disease, where aberrant tumor vasculature contributes to poor prognosis. To address the pharmacological limitations of regorafenib (REG), this study developed a dual-receptor-targeted nanoplatform (REG@LFHA NPs) that leverages the characteristic overexpression of LRP-1 and CD44 receptors in the colorectal cancer tumor microenvironment. The nanoplatform was engineered through nanoprecipitation and electrostatic self-assembly, incorporating lactoferrin for LRP-1 targeting and hyaluronic acid for CD44 recognition. REG@LFHA NPs exert multifaceted antitumor effects through three coordinated mechanisms: potent suppression of tumor vasculature through VEGF-VEGFR pathway blockade, effectively disrupting blood and oxygen supply to induce tumor necrosis; direct tumor cytotoxicity via REG-mediated apoptosis and cell cycle arrest; and immune microenvironment remodeling through macrophage repolarization from pro-tumor M2 to antitumor M1 phenotypes. In PM-CRC models, REG@LFHA NPs demonstrated significantly enhanced tumor accumulation and therapeutic efficacy compared to free REG. Furthermore, the nanoplatform showed remarkable synergy with oxaliplatin, the first-line chemotherapeutic agent for PM-CRC, producing superior treatment outcomes through complementary mechanisms of action. This study not only establishes REG@LFHA NPs as an effective dual-targeting nanomedicine but also demonstrates their strong potential for clinical translation, particularly in combination with standard chemotherapy regimens for advanced peritoneal metastatic colorectal cancer.

2026-04-01·JOURNAL OF INORGANIC BIOCHEMISTRY

Oxaliplatin-artesunate conjugate intensifies suppression on colorectal cancer by boosting antitumor immunity

Article

作者: Wang, Xiaoyong ; Cai, Linxiang ; Li, Shumeng ; Wang, Ying ; Guo, Zijian ; Tan, Yehong ; Yang, Tao ; Jiang, Siran

Immunosuppressive tumor microenvironment is the major obstacle for antitumor immunotherapy. Elimination of myeloid-derived suppressor cells (MDSCs) potentiates immunotherapy for various solid tumors. Oxaliplatin-artesunate complex OPA decreases MDSCs by inhibiting CD33 and the triggering receptor expressed on myeloid cells 2 (TREM2) in the TME, and enhancing dendritic cell maturation due to its ability to facilitate immunogenic cell death and activate the cyclic-GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. Moreover, OPA upregulates the costimulatory molecule CD28 and downregulates the immune checkpoint cytotoxic T lymphocyte-associated protein 4 (CTLA-4) on T cells, thus impeding the T cell depletion and immunosuppression. The activation of immune circulation and immunosignal pathway increases the chemotherapeutic activity of parent oxaliplatin. In addition, OPA serves as a cancer vaccine to inhibit tumor metastasis and reoccurrence. Lastly, the stability and safety profiles are superior to that of oxaliplatin. OPA is a unique chemoimmunotherapeutic agent with a distinct mechanism of action and prominent efficacy on orthotopic colorectal cancer in mouse models.

2,194

项与奥沙利铂相关的新闻（医药）

2026-01-28

·医药观澜

产业新闻丨恒瑞医药「瑞康曲妥珠单抗」治疗结直肠癌拟纳入优先审评

1月28日，中国国家药监局药品审评中心（CDE）官网最新公示，恒瑞医药申报的注射用瑞康曲妥珠单抗拟纳入优先审评，适用于经奥沙利铂、氟尿嘧啶和伊立替康治疗失败的HER2阳性结直肠癌成人患者。公开资料显示，瑞康曲妥珠单抗(SHR-A1811) 是一款以HER2为靶点的抗体偶联药物（ADC）。针对结直肠癌适应症，该产品此前已经被CDE纳入突破性治疗品种。瑞康曲妥珠单抗是恒瑞医药自主研发的以HER2为靶点的ADC，可特异性结合肿瘤细胞表面的HER2，随后偶联物被内吞至细胞内并转运至溶酶体中，通过蛋白酶切释放毒素在肿瘤细胞内产生药物作用，诱导肿瘤细胞的凋亡。其释放的毒素具有高透膜性，可发挥旁观者杀伤效应，进一步提高抗肿瘤疗效。 HER2异常广泛存在于多种实体瘤中，在结直肠癌（CRC）中HER2扩增发生率为5.8%，过表达发生率为5%，突变发生率为2%。晚期HER2阳性结直肠癌患者可选择的治疗有限，存在着巨大未被满足的临床需求。恒瑞医药此前在ESMO大会上公布了瑞康曲妥珠单抗治疗在HER2表达的结直肠癌（CRC）中1期临床试验结果。研究共入组43例CRC患者（HER2阳性率为86.0%；既往接受过≥2线治疗的患者为67.4%）。在推荐2期剂量下，CRC总体人群和HER2阳性CRC人群相应的客观缓解率分别为44.2%和46.9%；CRC总体人群和HER2阳性CRC人群相应的6个月无进展生存率分别为75.6%和85.5%。研究认为，SHR-A1811在HER2表达的CRC患者中显示出可接受的安全性特征和令人鼓舞的临床活性，值得进一步研究。本次瑞康曲妥珠单抗针对结直肠癌适应症拟纳入优先审评，意味着该产品有望加速来到患者身边。参考资料：[1]中国国家药监局药品审评中心（CDE）官网. From https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c [2]684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC).From https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal_2/presentation/list?q=684P 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

2026-01-27

·肿瘤防治在线

恶病质对胃部结合部腺癌的多维影响与临床挑战

点击蓝字关注我们胃部结合部腺癌（主要指胃食管结合部腺癌，GEJAC）作为消化系统恶性肿瘤中预后较差的类型，其治疗与预后常被恶病质显著影响。恶病质并非单纯的“消瘦”，而是由肿瘤驱动的、以肌肉/脂肪大量消耗为核心的复杂代谢紊乱综合征，在胃部结合部腺癌患者中发生率超40%，且直接关联治疗耐受性、复发风险与生存期，成为临床管理的关键障碍。从生理机制看，恶病质通过“代谢掠夺”与“功能破坏”双重作用削弱患者机体。一方面，肿瘤细胞持续释放肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）等炎症因子，加速肌肉蛋白分解与脂肪氧化，即使患者正常进食，也无法逆转“高消耗、低合成”的失衡状态——这对胃部结合部腺癌患者尤为致命，因该部位肿瘤本就易导致吞咽困难、胃排空障碍，患者摄入不足与恶病质的消耗形成“恶性循环”，短期内即可出现体重骤降（每月下降超5%）、乏力等症状。另一方面，恶病质引发的肌肉减少症（ sarcopenia ）会直接破坏机体基础功能，例如呼吸肌力量下降增加肺部感染风险，心肌肌肉流失可能诱发心功能不全，这些并发症会进一步降低患者对治疗的耐受阈值。在治疗层面，恶病质是胃部结合部腺癌规范治疗的“拦路虎”。对于可手术的患者，恶病质会显著提升围手术期风险：术前存在中重度恶病质（体重下降超10%或血清白蛋白＜30g/L）的患者，术后吻合口瘘发生率较无恶病质者高3倍，且因免疫功能低下（淋巴细胞计数减少、巨噬细胞活性降低），感染性并发症（如腹腔脓肿、肺炎）风险增加50%，部分患者甚至因身体状态差被迫取消手术，错失根治机会。而对于需接受化疗（如奥沙利铂联合卡培他滨方案）或靶向治疗（如曲妥珠单抗）的患者，恶病质会加剧治疗毒性：肌肉量不足会导致药物在体内代谢异常，相同剂量下更易出现骨髓抑制（白细胞、血小板减少）、消化道反应（呕吐、腹泻），约20%恶病质患者需因严重不良反应降低化疗剂量或延迟治疗，导致治疗强度不足，直接影响肿瘤控制效果。预后影响上，恶病质是胃部结合部腺癌患者的“独立不良预后因子”。临床数据显示，合并恶病质的胃部结合部腺癌患者，中位生存期较无恶病质者缩短40%-60%：Ⅰ-Ⅱ期患者若合并恶病质，5年生存率从60%降至35%以下；即使是接受根治性手术的患者，恶病质也会使肿瘤复发风险提升2.3倍，原因在于机体长期处于慢性炎症与免疫抑制状态，无法清除残存的肿瘤细胞，为复发转移埋下隐患。此外，恶病质引发的生活质量恶化也不容忽视——患者因持续乏力、食欲丧失、疼痛等症状，日常活动能力（如穿衣、行走）显著受限，心理状态也易陷入焦虑、抑郁，形成“生理-心理”双重困境，进一步削弱机体对抗肿瘤的能力。当前临床对恶病质的干预仍以“支持治疗”为主，核心是通过营养支持与药物干预延缓进展：营养层面，需根据患者吞咽与消化能力，选择肠内营养（如高能量密度的流质营养制剂）或肠外营养，补充蛋白质（每日1.2-1.5g/kg体重）与ω-3脂肪酸，减少肌肉分解；药物层面，甲地孕酮可改善食欲，奥曲肽能抑制炎症因子释放，但效果均存在个体差异。未来，随着靶向恶病质关键通路（如IL-6受体、泛素-蛋白酶体系统）的药物研发，或能为胃部结合部腺癌合并恶病质患者提供更精准的干预手段，打破“肿瘤进展-恶病质加重”的恶性循环。总体而言，恶病质对胃部结合部腺癌的影响贯穿疾病全程，从生理功能到治疗实施，再到最终预后，均形成显著负面影响。临床管理中，需将恶病质的评估（如定期监测体重、肌肉量、炎症指标）纳入常规诊疗流程，早识别、早干预，才能最大程度改善患者治疗耐受性与生存获益。【声明】本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被确切地视为诊疗建议。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。本文来自【天津市肿瘤医院苏雨栋教授】

2026-01-27

·同写意

豪掷60亿“扫货”，老牌巨头的“新药方”

抗体药物偶联物生物类似药上市批准引进/卖出

100 项与奥沙利铂相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01790	奥沙利铂	L01XA03	DB00526

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
小肠癌	日本	Takata Pharmaceutical Co. Ltd.	2018-09-21
小肠癌	日本	Yakult Honsha Co., Ltd.	2018-09-21
胃癌	日本	Takata Pharmaceutical Co. Ltd.	2015-03-20
胃癌	日本	Yakult Honsha Co., Ltd.	2015-03-20
胰腺癌	日本	Yakult Honsha Co., Ltd.	2013-12-20
胰腺癌	日本	Takata Pharmaceutical Co. Ltd.	2013-12-20
晚期胃癌	巴西	Libbs Farmacêutica Ltda.	2008-08-18
胃食管交界处癌	巴西	Libbs Farmacêutica Ltda.	2008-08-18
转移性结直肠癌	巴西	Libbs Farmacêutica Ltda.	2008-08-18
转移性胰腺腺癌	巴西	Libbs Farmacêutica Ltda.	2008-08-18
结直肠癌	美国	Sanofi-Aventis U.S. LLC	2007-01-10
晚期结直肠腺癌	澳大利亚	Medis Pharma Pty Ltd.	2006-11-28
结肠癌	美国	Sanofi-Aventis U.S. LLC	2002-08-09
直肠癌	美国	Sanofi-Aventis U.S. LLC	2002-08-09
肿瘤	中国	南京制药厂有限公司	2000-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性弥漫性大B细胞淋巴瘤	临床3期	美国	Hoffmann-La Roche, Inc.	2021-02-23
复发性弥漫性大B细胞淋巴瘤	临床3期	中国	Hoffmann-La Roche, Inc.	2021-02-23
复发性弥漫性大B细胞淋巴瘤	临床3期	澳大利亚	Hoffmann-La Roche, Inc.	2021-02-23
复发性弥漫性大B细胞淋巴瘤	临床3期	比利时	Hoffmann-La Roche, Inc.	2021-02-23
复发性弥漫性大B细胞淋巴瘤	临床3期	丹麦	Hoffmann-La Roche, Inc.	2021-02-23
复发性弥漫性大B细胞淋巴瘤	临床3期	法国	Hoffmann-La Roche, Inc.	2021-02-23
复发性弥漫性大B细胞淋巴瘤	临床3期	德国	Hoffmann-La Roche, Inc.	2021-02-23
复发性弥漫性大B细胞淋巴瘤	临床3期	波兰	Hoffmann-La Roche, Inc.	2021-02-23
复发性弥漫性大B细胞淋巴瘤	临床3期	韩国	Hoffmann-La Roche, Inc.	2021-02-23
复发性弥漫性大B细胞淋巴瘤	临床3期	西班牙	Hoffmann-La Roche, Inc.	2021-02-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01532804 (BEVATOMOX, Pubmed \| Oncologist)	临床2期	转移性结直肠癌二线	83	Raltitrexed/Oxaliplatin/Bevacizumab	積願壓構醖顧築繭鹹鏇(鹹衊鑰壓壓窪艱鬱膚衊) = 襯糧艱餘選簾餘選鏇廠簾衊顧淵積簾積構鹽構 (遞膚築醖觸醖構鹽觸顧, 26 ~ 51) 更多	积极	2026-01-14
NCT01532804 (BEVATOMOX, Pubmed \| Oncologist)	临床2期	转移性结直肠癌二线	83	mFOLFOX6/Bevacizumab	積願壓構醖顧築繭鹹鏇(鹹衊鑰壓壓窪艱鬱膚衊) = 襯顧齋糧構範願餘獵鏇簾衊顧淵積簾積構鹽構 (遞膚築醖觸醖構鹽觸顧, 36 ~ 67) 更多	积极	2026-01-14
NCT04539808 (NeoOPTIMIZE, CTgov)	临床2期	胰腺腺癌 \| 胰腺导管腺癌	42	mFOLFIRINOX+nab-paclitaxel+leucovorin calcium+gemcitabine hydrochloride+potassium+losartan+Oxaliplatin+irinotecan hydrochloride+capecitabine+fluorouracil	願製餘壓廠選範齋鬱鑰 = 觸鬱鬱積遞衊壓鏇構衊壓鹹襯餘淵簾膚廠願糧 (壓鹽膚餘窪觸蓋鹽顧鏇, 範願獵餘鬱選壓鹹糧衊 ~ 窪窪築淵觸憲膚遞餘繭) 更多	-	2026-01-14
NCT01795027 (CAPITAL, ASCO_GI2026)	临床3期	胃食管交界处腺癌辅助	724	SOX regimen (S-1 + oxaliplatin)	醖壓鏇醖獵製願夢餘構(構築繭衊繭獵獵製醖遞) = neutropenia (44 (13%) of 349 patients in the SOX group and 23 (7%) of 347 patients in the S-1 group). 網糧鑰鹽鬱膚齋襯獵艱 (鑰範膚淵範淵蓋廠憲襯 ) 更多	积极	2026-01-08
NCT01795027 (CAPITAL, ASCO_GI2026)	临床3期	胃食管交界处腺癌辅助	724	S-1 regimen		积极	2026-01-08
OGSG1902 (ASCO_GI2026)	临床2期	胃癌新辅助	48	Neoadjuvant DOS therapy (docetaxel 40 mg/m2 and oxaliplatin 100 mg/m2 intravenously on day 1, and oral S-1 at 80 mg/m2 for 14 days)	範顧憲壓顧廠繭繭築鏇(艱顧淵鏇繭鬱積獵願網) = 獵願觸鹹獵鏇蓋築鏇構製醖醖憲憲醖糧膚遞憲 (艱衊觸鏇觸鑰壓餘積遞, 24.1 ~ 50.6) 更多	不佳	2026-01-08
JPRN-jRCTs031180028 (JCOG1704, ASCO_GI2026)	临床2期	胃癌 HER2-negative	47	Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 (DOS)	齋構製顧淵鹽繭獵積願(鹽願鏇範壓簾夢顧鑰鹽) = 糧鬱艱鏇鏇蓋範餘觸鹽觸糧廠鹹觸壓積窪醖糧 (淵糧艱鬱蓋艱積願鑰鬱, 72.7 ~ 93.7) 更多	积极	2026-01-08
JPRN-jRCTs031200094 (ASCO_GI2026)	临床2期	食管鳞状细胞癌新辅助	53	Neoadjuvant fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy	壓構簾壓鹹糧鹹廠選鏇(簾顧遞鹹鑰醖憲膚獵積) = 鹹醖築顧遞鹽壓製簾願鏇襯艱夢艱網鑰網願顧 (廠簾顧顧鏇壓餘範選觸 ) 更多	积极	2026-01-08
JPRN-jRCTs031200094 (ASCO_GI2026)	临床2期	食管鳞状细胞癌新辅助	53	Neoadjuvant fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy (without SCLN metastasis)	壓構簾壓鹹糧鹹廠選鏇(簾顧遞鹹鑰醖憲膚獵積) = 鑰膚襯餘遞鹽齋壓壓構鏇襯艱夢艱網鑰網願顧 (廠簾顧顧鏇壓餘範選觸 ) 更多	积极	2026-01-08
NCT04417699 (SHORT, CTgov)	临床2期	直肠癌 \| 直肠腺癌	13	TAS 102+oxaliplatin	憲簾積範鏇獵襯範襯鹹(築積鏇艱觸鹹壓鬱淵蓋) = 窪襯淵齋鏇窪餘鬱繭壓衊簾鬱醖遞築製艱夢衊 (齋獵鑰衊觸醖鹽構醖蓋, 13.41) 更多	-	2025-12-10
NCT04663347 (EPCORE NHL-2, ASH2025)	临床1期	复发性弥漫性大B细胞淋巴瘤 CD20+	103	Epcoritamab + GemOx	選齋蓋鹹顧齋壓選襯憲(醖淵繭壓獵鏇夢憲網觸) = 遞簾範範鏇艱蓋廠襯願糧築淵壓夢夢壓獵鏇襯 (夢襯繭鬱遞糧窪壓製網 ) 更多	积极	2025-12-06
NCT01270724 (CTgov)	临床2期	皮样囊肿 \| 畸胎瘤 \| 内胚层窦瘤 ... 更多	10	Paclitaxel+Gemcitabine+Oxaliplatin	構鑰繭窪鹽糧積願糧顧 = 鑰夢製鏇繭淵範遞積鹹淵夢構壓簾觸顧艱鏇夢 (膚鹽製繭願鏇醖糧鹽廠, 艱壓繭蓋鹽憲夢鏇選觸 ~ 鏇壓鬱鹽蓋淵繭網製築) 更多	-	2025-10-27
NCT03164655 (SULTAN UCGI 30/PRODIGE 53, Pubmed \| Ann Surg Oncol)	临床2期	结直肠癌肝转移	26	Hepatic Arterial Infusion (HAI) oxaliplatin + systemic chemotherapy (sys-CT)	鹹構淵觸鹽淵蓋簾淵網(選簾鏇獵製鏇鬱糧醖艱) = 艱糧醖獵壓衊網簾網鹽淵築簾淵鹽夢構積願願 (積簾鑰壓窪鹹獵範壓淵 ) 更多	不佳	2025-10-21
	临床2期	结直肠癌肝转移	26	systemic chemotherapy (sys-CT)	鹹構淵觸鹽淵蓋簾淵網(選簾鏇獵製鏇鬱糧醖艱) = 餘鹹製鑰獵選齋鑰齋憲淵築簾淵鹽夢構積願願 (積簾鑰壓窪鹹獵範壓淵 ) 更多	不佳	2025-10-21